Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Researchers from the University of Oxford and their partners have today reported findings from a Phase IIb trial of a candidate malaria vaccine, R21/Matrix-M, which demonstrated high-level efficacy of 77% over 12-months of follow-up.

Technician working in the lab, Nanoro
  • High-level vaccine efficacy of 77% in African children achieve WHO-specified efficacy goal of 75%
  • Vaccine, trialled in 450 children, shows favourable safety profile and was well-tolerated
  • Vaccine candidate, R21/Matrix-M, has excellent potential for large-scale manufacturing and low-cost supply

In their findings they note that they are the first to meet the World Health Organization’s Malaria Vaccine Technology Roadmap goal of a vaccine with at least 75% efficacy.

Read the full story on the University of Oxford website